Amivantamab with chemotherapy for previously untreated advanced EGFR exon 20 insertion mutations positive non-small cell lung cancer

Amivantamab in combination with carboplatin-pemetrexed chemotherapy is in development for
the treatment of epidermal growth factor receptor (EGFR) exon 20 insertion mutations positive
non-small cell lung cancer (NSCLC). NSCLC is one of the most common types of cancer. EGFR is
a protein found on certain types of cells that is involved in cell signalling pathways that control
cell division and survival. Mutations in this protein can cause increased cell division resulting in
tumour growth. Patients with EGFR exon 20 insertion mutations have worse prognosis than those
with common EGFR mutations. There are currently no recommended NICE treatment options for
this specific indication highlighting the need for a therapy.